Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 711–720 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 711
- Medicine slug
- hydrochlorothiazide
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 144
- Source count
- 35
- Agreement rate
- 1
- Recorded readings
1 to 5 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 35
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 35 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02a481cb-ad80-41bb-82d3-c237b00ed8d7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98edae8a-99dc-4f26-a956-3ad58bf38a26 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e31bd548-29ae-419a-831a-80ebb26e042f (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef56450d-86d3-2654-e053-2995a90a142c (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39d4dbd3-8f24-4898-a240-e94e06fa229a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd5728a2-6322-42e3-bd1e-e4915750e398 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2de8e26-ef5a-41c7-888b-990629b11145 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ad0fdf-5d47-4c2d-883b-f28b2d3fb6b0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL follow‑ing oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:578f74ea-53d1-4c44-b872-66033292abe0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45316037-52ec-438f-8780-b2e983fef3f5 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:918391e3-e8b3-4ceb-b4e7-c7c9617ea882 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f7a608d-748b-49a9-a4b3-b3fdcab53ce0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:911a18c1-120a-46b3-b7a8-25eb37843473 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:460f922c-1fda-44a5-889e-d7009883176b (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1052d38-fd75-40c2-a685-0e889009be0b (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b993f2-9771-42e3-b10e-09719189e2bd (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b54ec2b1-3325-46a1-b654-8a75dc41ab0a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb7712f3-9a0b-442d-859d-8be5e6e2529a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8242c1de-f482-4a85-b977-610e71fa4904 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13ed002f-c5bb-401c-891a-70b70cbd8fb6 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32ce8fe-6cbc-8a15-e053-2995a90a8eec (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb7b7315-0170-492c-803f-60a6e75e55da (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b21f3fc-4164-401a-803e-b982dea97e19 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3afa83d-c79c-848a-e053-2a95a90ac922 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69c41abb-75f4-429b-905a-1ce967924aee (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3eb7294-f913-434b-896c-da028bfebc73 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:841b7962-bf5d-4c45-b594-80b17ba5187d (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6b933c6-f5f8-406a-84d6-b22c6040482a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bacc909-6b02-4815-85ef-55fd25b1b1f7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0789baef-3424-43ab-a3fb-4908172da565 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a11a458-dc69-40ba-a58a-649733e0e8ab (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34703033-14c4-459c-8b8f-2f2e1145aff7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fc94bc2-fa38-439a-a609-1b4130cdacb1 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff557069-f177-4e2e-91f4-675a033e2739 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f9c3ae-108d-469e-af6c-8be3b0f83139 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
Projected row 712
- Medicine slug
- hydrocodone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 0.666667
- Recorded readings
7 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b55d14-0980-b680-8ceb-7489ff65455e (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
The mean terminal half-life (t 1/2 ) at steady state was 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7d23ac2-e776-9f62-3290-c64c2d6eb353 (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
The mean terminal half-life (t 1/2 ) at steady state was 7 hours.
3 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7b8ea07-e926-f0a5-c20d-92f23ed350d0 (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
Based on the half-life of hydrocodone, steady-state should be obtained after 3 days of dosing.
Projected row 713
- Medicine slug
- hydrocodone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
33%
- Numeric value
- 33
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b55d14-0980-b680-8ceb-7489ff65455e (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
The mean in vivo plasma protein binding of hydrocodone across the groups was similar, ranging from 33% to 37% [see Use in Specific Populations ( 8.6 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7d23ac2-e776-9f62-3290-c64c2d6eb353 (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
The mean in vivo plasma protein binding of hydrocodone across the groups was similar, ranging from 33% to 37% [see Use in Specific Populations (8.6) ].
Projected row 714
- Medicine slug
- hydrocodone
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 0.666667
- Recorded readings
14 to 16 hours
- Numeric value
- 14
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b55d14-0980-b680-8ceb-7489ff65455e (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Hydrocodone bitartrate extended-release tablets are a single-entity extended-release formulation of hydrocodone that yields a gradual increase in plasma hydrocodone concentrations with a median T max of 14 to 16 hours noted for different dose strengths.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7d23ac2-e776-9f62-3290-c64c2d6eb353 (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption HYSINGLA ER is a single-entity extended-release formulation of hydrocodone that yields a gradual increase in plasma hydrocodone concentrations with a median T max of 14 – 16 hours noted for different dose strengths.
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7b8ea07-e926-f0a5-c20d-92f23ed350d0 (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
Hydrocodone bitartrate extended-release capsules exhibit peak plasma concentrations approximately 5 hours after dose administration.
Projected row 715
- Medicine slug
- hydrocodone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
402 L
- Numeric value
- 402
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b55d14-0980-b680-8ceb-7489ff65455e (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
Distribution Following administration of hydrocodone bitartrate extended-release tablets, the typical (70 kg adult) value of apparent volume of distribution (V/F) is 402 L, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7d23ac2-e776-9f62-3290-c64c2d6eb353 (opens source in a new tab)
Hydrocodone label
Version not recorded · Effective date not recorded
Distribution Following administration of HYSINGLA ER, the typical (70 kg adult) value of apparent volume of distribution (V/F) is 402 L, suggesting extensive tissue distribution.
Projected row 716
- Medicine slug
- hydromorphone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 31
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
24%
- Numeric value
- 24
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d88866-e1ba-9d97-e063-6394a90a7b27 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c48e2e9a-cb5b-46b8-b6be-3dd76e80d0ca (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8fd7b0e-22b9-4f8a-8eb2-41d5031779af (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de15afe-d676-4faa-a34d-9b9cb20dbf54 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc574063-6ede-4da7-82c4-7450c92b229b (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bec32a94-4b79-4bd4-b000-45e9030d3106 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18f6f54e-1537-4181-9d07-54ddf881a9ee (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4758743-9b2c-4612-8399-ad2db372e2b7 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f778dfab-e109-428e-b1b7-4dfb1b8293e4 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fab97112-e276-40e0-bc82-0a29d7fa75fa (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ddcacc-99e4-8b21-e063-6394a90a3e79 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c5c1cc8-c42b-46e3-ad68-8e22f57101f2 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bfbba46-1979-4797-a29e-d67718131686 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2427814c-f32b-8ac5-99b8-5e886fd2d001 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29765ff0-3b1d-47da-953e-28bf0e6a56ef (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37565441-0d95-4743-a695-d7b3326f58a1 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6b40e39-a57e-402c-b4f6-7041e832f837 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).
Projected row 717
- Medicine slug
- hydromorphone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 31
- Source count
- 30
- Agreement rate
- 0.8
- Recorded readings
2.3 hours
- Numeric value
- 2.3
- Unit
- hours
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e034eb96-03e0-46e1-8b92-5e1f94555e7b (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c729424e-e483-4bf8-b86c-ce56636dcffa (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eebd88a-5632-460f-b7b6-26c8a180540d (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d88866-e1ba-9d97-e063-6394a90a7b27 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c48e2e9a-cb5b-46b8-b6be-3dd76e80d0ca (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c9ef18-7dfc-4322-b2fc-29b934c30f8b (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31d5a37a-0e90-4e88-be14-75c877be9de2 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc574063-6ede-4da7-82c4-7450c92b229b (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9ca2ef5-46d8-475a-a26e-f7c8becd6db7 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bec32a94-4b79-4bd4-b000-45e9030d3106 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18f6f54e-1537-4181-9d07-54ddf881a9ee (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4758743-9b2c-4612-8399-ad2db372e2b7 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b78db9-a38c-41bb-8233-5e93f7f18c5c (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f778dfab-e109-428e-b1b7-4dfb1b8293e4 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fab97112-e276-40e0-bc82-0a29d7fa75fa (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ddcacc-99e4-8b21-e063-6394a90a3e79 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c5c1cc8-c42b-46e3-ad68-8e22f57101f2 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bfbba46-1979-4797-a29e-d67718131686 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3832ede8-d3fc-455d-ecab-3b77be5869f5 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2427814c-f32b-8ac5-99b8-5e886fd2d001 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e79859-4efc-4ea7-8211-cadf746bc864 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29765ff0-3b1d-47da-953e-28bf0e6a56ef (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37565441-0d95-4743-a695-d7b3326f58a1 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6b40e39-a57e-402c-b4f6-7041e832f837 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
11 hours
- Numeric value
- 11
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:780a2616-0392-4715-bc50-71799bea1957 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The mean half-life was approximately 11 hours, ranging from 8 to 15 hours in most individual subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c33e6320-4206-4b69-8cac-ebfc2351b8f2 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The mean half-life was approximately 11 hours, ranging from 8 to 15 hours in most individual subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90bda45c-9dbe-4ed5-91d0-df8446ad7026 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The mean half-life was approximately 11 hours, ranging from 8 to 15 hours in most individual subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bb81796-6990-40e9-bee4-1f292f91ae99 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
The mean half-life was approximately 11 hours, ranging from 8 to 15 hours in most individual subjects.
40 hr
- Numeric value
- 40
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8fd7b0e-22b9-4f8a-8eb2-41d5031779af (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In addition, in patients with severe renal impairment hydromorphone appeared to be more slowly eliminated with longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4de15afe-d676-4faa-a34d-9b9cb20dbf54 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
In addition, in patients with severe renal impairment hydromorphone appeared to be more slowly eliminated with longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr).
Projected row 718
- Medicine slug
- hydromorphone
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 31
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
16 hours
- Numeric value
- 16
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:780a2616-0392-4715-bc50-71799bea1957 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
When a 16 mg dose of hydromorphone hydrochloride extended-release tablets was administered to healthy volunteers immediately following a high-fat meal, the median time to C max (T max ) was minimally affected by the high-fat meal occurring at 16 hours compared to 18 hours while fasting.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c33e6320-4206-4b69-8cac-ebfc2351b8f2 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
When a 16 mg dose of hydromorphone hydrochloride extended-release tablets was administered to healthy volunteers immediately following a high-fat meal, the median time to C max (T max ) was minimally affected by the high-fat meal occurring at 16 hours compared to 18 hours while fasting.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90bda45c-9dbe-4ed5-91d0-df8446ad7026 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
When a 16 mg dose of hydromorphone hydrochloride extended-release tablets was administered to healthy volunteers immediately following a high-fat meal, the median time to C max (T max ) was minimally affected by the high-fat meal occurring at 16 hours compared to 18 hours while fasting.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bb81796-6990-40e9-bee4-1f292f91ae99 (opens source in a new tab)
Hydromorphone label
Version not recorded · Effective date not recorded
When a 16 mg dose of hydromorphone hydrochloride extended-release tablets were administered to healthy volunteers immediately following a high-fat meal, the median time to C max (T max ) was minimally affected by the high-fat meal occurring at 16 hours compared to 18 hours while fasting.
Projected row 719
- Medicine slug
- hydroxychloroquine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 49
- Source count
- 39
- Agreement rate
- 1
- Recorded readings
79%
- Numeric value
- 79
- Unit
- %
- Source records
- 39
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 39 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:805a1acd-2e0d-48f1-af6b-0e5d8e06c228 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e09aeca-0cec-4a88-9dde-a2098a08b877 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6837f2aa-1349-4b45-a0ac-09ec914fd764 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81e68f23-b1bf-4561-8f02-a472631acfaf (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2d7be5a-98ee-4292-8715-46573dbe1c5b (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a06ad3d-2d6c-4e51-93f5-8f782b86975b (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a39c45e-dc14-4441-9b02-7329647bc5a4 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68d6439d-b927-47e6-86ef-20e572e81941 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebe00e35-ed3d-40f4-9a93-a37b0da01ddb (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84957919-ca14-4c3d-b4fe-452ff330dd7a (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd441154-b196-4d4c-bc56-2e37f345ef8d (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a9e2fc8-bedf-46d4-9973-328dbcb18061 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fe2ece-40a1-49eb-818f-62ff3c3bb199 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517ee47b-6abf-43cb-a4ca-c2e7827461a8 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7804f5d2-41a6-4523-a277-6967e984e88e (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f618a091-ade1-4c39-ab76-f6218b606e05 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53553ef5-5f44-4d39-ae8c-c9a632cc8416 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f3e49b2-dc11-40a9-b366-c88e36a471e5 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87076a61-ce76-475b-ac6d-c33ba617195d (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4b1912-9806-4ef3-bf17-152a96d75bbc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f95cfc03-5023-44b3-8994-25afac18b734 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427ac2fc-8f7f-9725-e063-6394a90a381b (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4902343c-7d1b-ba70-e063-6294a90a3680 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:452092b4-7a8f-4d19-8113-f1c2a948d3d8 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29ba0172-7ca3-4122-af1b-f0da522318cb (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3817387f-2fc8-4f39-8096-3b48fff57ab0 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84b00366-96ef-41e1-bac6-5d24acdb9e1d (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c8ee2e-116e-4167-8d1a-bd570a1ce672 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34496b43-05a2-45fb-a769-52b12e099341 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6f889ff-c5ba-4324-b87c-ec3ac942be2f (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19816051-c25e-44b5-a127-e846dbd0a8d8 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04d8fdbf-8829-4469-a341-8af2a2d91ccc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dfa0ff8-e8cf-47f9-847a-b86f23dc39df (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2eeaf562-95f9-bcef-e063-6394a90a1c19 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04139607-f7c0-4fe1-a210-ffa5af347d56 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37413f6b-fb68-4e0c-8bcc-c5b76e956dfc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a1fb21d-a01c-4d50-8764-cdd6c20d9569 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c109188-d28b-4c65-8b52-819bd8547f2e (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6971241c-8323-456e-91a4-a404a9e100de (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.
Projected row 720
- Medicine slug
- hydroxychloroquine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 49
- Source count
- 49
- Agreement rate
- 0.918367
- Recorded readings
3 to 4 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 45
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 45 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:805a1acd-2e0d-48f1-af6b-0e5d8e06c228 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e09aeca-0cec-4a88-9dde-a2098a08b877 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6837f2aa-1349-4b45-a0ac-09ec914fd764 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb26c050-fc41-4183-9f8c-86351335fa64 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81e68f23-b1bf-4561-8f02-a472631acfaf (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2d7be5a-98ee-4292-8715-46573dbe1c5b (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a06ad3d-2d6c-4e51-93f5-8f782b86975b (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a39c45e-dc14-4441-9b02-7329647bc5a4 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68d6439d-b927-47e6-86ef-20e572e81941 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebe00e35-ed3d-40f4-9a93-a37b0da01ddb (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84957919-ca14-4c3d-b4fe-452ff330dd7a (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd441154-b196-4d4c-bc56-2e37f345ef8d (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4dca05a-745f-4c15-b731-1e99176cf44c (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a9e2fc8-bedf-46d4-9973-328dbcb18061 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fe2ece-40a1-49eb-818f-62ff3c3bb199 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517ee47b-6abf-43cb-a4ca-c2e7827461a8 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7804f5d2-41a6-4523-a277-6967e984e88e (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beff29fe-574f-4566-99ac-53ec3b3038a7 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f618a091-ade1-4c39-ab76-f6218b606e05 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53553ef5-5f44-4d39-ae8c-c9a632cc8416 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f3e49b2-dc11-40a9-b366-c88e36a471e5 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87076a61-ce76-475b-ac6d-c33ba617195d (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4b1912-9806-4ef3-bf17-152a96d75bbc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f95cfc03-5023-44b3-8994-25afac18b734 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427ac2fc-8f7f-9725-e063-6394a90a381b (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4902343c-7d1b-ba70-e063-6294a90a3680 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:452092b4-7a8f-4d19-8113-f1c2a948d3d8 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83cb17e9-ce57-48aa-b92c-ac0dee92d5bc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29ba0172-7ca3-4122-af1b-f0da522318cb (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3817387f-2fc8-4f39-8096-3b48fff57ab0 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84b00366-96ef-41e1-bac6-5d24acdb9e1d (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c8ee2e-116e-4167-8d1a-bd570a1ce672 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34496b43-05a2-45fb-a769-52b12e099341 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6f889ff-c5ba-4324-b87c-ec3ac942be2f (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da435181-0c5a-4188-8d59-51234116b005 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19816051-c25e-44b5-a127-e846dbd0a8d8 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04d8fdbf-8829-4469-a341-8af2a2d91ccc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dfa0ff8-e8cf-47f9-847a-b86f23dc39df (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2eeaf562-95f9-bcef-e063-6394a90a1c19 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04139607-f7c0-4fe1-a210-ffa5af347d56 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37413f6b-fb68-4e0c-8bcc-c5b76e956dfc (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e72fe06-7995-3fd7-e053-2a91aa0a54db (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a1fb21d-a01c-4d50-8764-cdd6c20d9569 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c109188-d28b-4c65-8b52-819bd8547f2e (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6971241c-8323-456e-91a4-a404a9e100de (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood.
537 hours
- Numeric value
- 537
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5b3455a-e842-7d4b-e053-2995a90adee3 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Pharmacokinetics: Following a single 200 mg oral dose of hydroxychloroquine sulfate tablets to healthy male volunteers, the mean peak blood concentration of hydroxychloroquine was 129.6 ng/mL, reached in 3.26 hours with a half-life of 537 hours (22.4 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aec894d-5711-4079-b167-240713bf04f2 (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
Pharmacokinetics : Following a single 200 mg oral dose of PLAQUENIL to healthy male volunteers, the mean peak blood concentration of hydroxychloroquine was 129.6 ng/mL, reached in 3.26 hours with a half-life of 537 hours (22.4 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90111c26-cd12-4a45-a25f-8d83c83c80de (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics Following a single 200 mg oral dose of hydroxychloroquine sulfate to healthy males, the mean peak blood concentration of hydroxychloroquine was 129.6 ng/mL, reached in 3.26 hours with a half-life of 537 hours (22.4 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8e3a352-a1e3-e672-e053-2a95a90a641c (opens source in a new tab)
Hydroxychloroquine label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics Following a single 200 mg oral dose of hydroxychloroquine sulfate to healthy males, the mean peak blood concentration of hydroxychloroquine was 129.6 ng/mL, reached in 3.26 hours with a half-life of 537 hours (22.4 days).
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=710Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.